Therapeutics News and Research

RSS

Urine RNA analysis shows promise for detecting genitourinary diseases

Early detection is critical when it comes to curing diseases like cancer, but not everyone has easy access to screening tools.

23 Oct 2024

Southwest Research Institute breaks ground on new clinical supply facility

Southwest Research Institute broke ground today on a new 21,000-square-foot Clinical Supply Facility to support government and industry clients with integrated pharmaceutical and bioengineering research and development.

23 Oct 2024

Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments

Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2).

23 Oct 2024

Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate.

23 Oct 2024

New drug WNTinib shows promise in treating pediatric liver cancer

A new drug called WNTinib can delay the growth of tumors and improve survival in hepatoblastoma, a type of liver cancer that occurs in young children.

22 Oct 2024

FDA funding fuels research on turkey parasite and potential treatments

As scientists learn more about a deadly parasite's ability to move from host to host in turkey flocks, a long-standing theory is in question and opens the door to new preventative measures.

22 Oct 2024

INTEGRA Biosciences’ pipettes help progress small molecule inhibitors from discovery to clinical trials

RAPT Therapeutics in San Francisco, USA, relies on INTEGRA Biosciences’ pipettes to seamlessly accelerate the development of its candidate small molecule inhibitors for the treatment of inflammatory diseases and cancers.

From INTEGRA Biosciences 22 Oct 2024

Optibrium demonstrates superior molecular docking method for small molecules and macrocycles

Optibrium, a leading developer of software and AI solutions for molecular design today announced the publication of a peer-reviewed study in the Journal of Computer-Aided Molecular Design, 'Structure-Based Pose Prediction: Non-cognate Docking Extended to Macrocylic Ligands'.

From Optibrium Ltd. 22 Oct 2024

New antibody targets cancer-causing HER2 mutations

For some proteins, a single mutation, or change in its DNA instructions, is all it takes to tip the balance between functioning normally and causing cancer.

22 Oct 2024

Rising asthma rates in sub-Saharan Africa linked to urbanization and lack of care

Rapid urbanization and population growth in sub-Saharan Africa has increased the incidence of asthma in young people, but the lack of diagnosis and care means that many young people are suffering from untreated symptoms of asthma, according to research from Queen Mary University of London.

21 Oct 2024

Novel antibodies show promise for tumor targeting and RAD51 inhibition

A new research paper was published in Oncotarget's Volume 15 on October 1, 2024, entitled, "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition."

21 Oct 2024

Ubiquigent partners with Alleo Labs to advance DUB-targeting therapies

Ubiquigent Limited (“Ubiquigent”), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases.

18 Oct 2024

Revealing the hidden role of blood leaks in Alzheimer’s and MS

The question of what causes complex neurological diseases such as Alzheimer's or multiple sclerosis continues to confound scientists and doctors, with the unknowns standing in the way of early diagnoses and effective treatments.

18 Oct 2024

New grant aims to transform treatment for liver cancer

Currently, there are a few available treatment options for liver cancer, including a combination of immunotherapies and a class of drugs known as tyrosine kinase inhibitors (TKIs), but their long-term effects are limited.

17 Oct 2024

Trial evaluates monoclonal antibodies for long COVID prevention

The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine.

17 Oct 2024

Discovering new natural products from human microbiomes

The idea of using microorganisms as a source of new active ingredients is not new. Numerous drugs have already been developed on the basis of natural products from bacteria and fungi.

17 Oct 2024

A review of clinical features, diagnosis, and management of Mpox

A comprehensive review in JAMA outlines monkeypox's clinical presentation and management, stressing the need for increased surveillance and vaccination efforts.

17 Oct 2024

Assessing and addressing IP staffing needs in a pediatric setting

A new paper published today in the American Journal of Infection Control (AJIC) describes efforts at a major children's hospital to assess and fulfill its staffing needs for infection prevention and control, highlighting the challenges of allocating sufficient resources to this important role.

17 Oct 2024

Study shows safety of kidney transplants among those with HIV infections

It is just as safe and effective for people with HIV in need of kidney transplantation to get their organ from donors who are also HIV positive as it is from donors who are not infected with the virus, a new study shows.

16 Oct 2024

Adenine base editors show potential to correct X-CGD-causing mutations

A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder characterized by high susceptibility to infections.

16 Oct 2024